Wilfredo Alonso, MD
Internal Medicine · Aguadilla, PRNPI 1790923050
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,753 of the $5,443 with a category attached, or 87.3%. 19 manufacturers reported payments, led by Johnson & Johnson at 28.9% of the total. Reporting peaked in 2021 at $1,498 and has fallen 68.0% since, to $480 in 2025. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $36.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AstraZeneca$1K
- Boehringer Ingelheim$668
- E.r. Squibb & Sons, L.L.C.$614
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$300
- Dexcom, Inc.$150
- plus $678 from 13 others
What the payments were for
- Consulting fees$69013%
- Food & beverage$4,75387%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $1,573 |
| AstraZeneca | 54 | $1,459 |
| Boehringer Ingelheim | 18 | $668 |
| E.r. Squibb & Sons, L.L.C. | 12 | $614 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $300 |
| Dexcom, Inc. | 2 | $150 |
| PBG Puerto Rico LLC | 7 | $147 |
| Medtronic | 1 | $109 |
| Boston Scientific | 1 | $83 |
| GSK | 1 | $74 |
| Bayer Puerto Rico Inc. | 2 | $60 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Pfizer | 1 | $32 |
| Eli Lilly Export S.A. Puerto Rico Branch | 2 | $26 |
| Abbott | 1 | $23 |
| Shire North American Group Inc | 1 | $23 |
| AbbVie | 1 | $22 |
| Pfizer Pharmaceuticals LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,443 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 126 | $99,094 |
| EliquisApixaban | 89 | $64,079 |
| JardianceEmpagliflozin | 65 | $61,584 |
| TrulicityDulaglutide | 22 | $29,299 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 36 | $29,021 |
| XareltoRivaroxaban | 27 | $22,236 |
| LantusInsulin Glargine,hum.Rec.Anlog | 182 | $18,588 |
| SynthroidLevothyroxine Sodium | 199 | $18,490 |
| Candesartan Cilexetil | 109 | $14,923 |
| BrilintaTicagrelor | 24 | $13,828 |
| EntrestoSacubitril/Valsartan | 18 | $13,041 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $12,957 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $10,852 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 17 | $9,520 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $9,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $1,459 | $112,922150 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr | $668 | $81,955100 claims |
| PfizerEliquis | $32 | $64,07989 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $12 | $47,609218 claims |
| Johnson & JohnsonXarelto | $1,573 | $22,23627 claims |
| AbbVieSynthroid | $22 | $18,490199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Aguadilla
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$351K
- Ronald Collazo PaganManati$206K
- Angel VinuelaDorado$182K
- Julio JimenezSan Lorenzo$99K
- Luis Negron GarciaSan German$24K
- Jorge Torres OlmedaCoto Laurel$23K
- Norma SalgadoSan Juan$21K
- Victor Gordo GonzalezSan Juan$21K
- Luis Rivera ColonRio Piedras$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.